Gambaran Umum
Denali Therapeutics Inc., based in the United States, operates primarily within the biotechnology industry, focusing on the discovery and development of therapies for patients with neurodegenerative diseases such as Alzheimer's, Parkinson's, ALS, and others. The company leverages its proprietary technology platforms to create a pipeline of potential therapeutics aimed at treating these complex diseases. Key projects include their RIPK1 inhibitor program, aimed at tackling neuroinflammation, and their LRRK2 inhibitor program, addressing genetic mutations associated with Parkinson’s disease. Denali’s approach emphasizes rigorous biomarker and genetic validation to advance their projects from preclinical stages toward clinical trials, aiming to meet significant unmet medical needs in neurodegenerative conditions.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk Denali Therapeutics Inc. per 2025 Jun 30 adalah -533.58 MM.
- Nilai net income untuk Denali Therapeutics Inc. per 2025 Jun 30 adalah -479.03 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -533.58 | -479.03 | |
2025-03-31 | -515.21 | -453.94 | |
2024-12-31 | -501.88 | -422.77 | |
2024-09-30 | 0.00 | -512.50 | -427.49 |
2024-06-30 | 1.27 | -495.21 | -419.65 |
2024-03-31 | 295.39 | -208.14 | -137.25 |
2023-12-31 | 330.53 | -196.70 | -145.22 |
2023-09-30 | 340.81 | -161.57 | -124.43 |
2023-06-30 | 343.11 | -163.16 | -128.38 |
2023-03-31 | 101.46 | -395.06 | -370.55 |
2022-12-31 | 108.46 | -340.74 | -325.99 |
2022-09-30 | 110.69 | -312.52 | -302.57 |
2022-06-30 | 112.42 | -290.63 | -283.86 |
2022-03-31 | 82.88 | -291.03 | -285.76 |
2021-12-31 | 48.66 | -295.75 | -290.58 |
2021-09-30 | 352.96 | 25.45 | 29.57 |
2021-06-30 | 357.07 | 50.92 | 55.92 |
2021-03-31 | 339.98 | 51.47 | 57.86 |
2020-12-31 | 335.66 | 62.72 | 71.14 |
2020-09-30 | 23.52 | -239.12 | -227.77 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Denali Therapeutics Inc. pada 2025 Jun 30 adalah -2.81.
- laba per saham yang terdilusi untuk Denali Therapeutics Inc. pada 2025 Jun 30 adalah -2.81.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -2.81 | -2.81 |
2025-03-31 | -2.67 | -2.67 |
2024-12-31 | -2.57 | |
2024-09-30 | -2.73 | -2.74 |
2024-06-30 | -2.83 | -2.82 |
2024-03-31 | -0.98 | -0.98 |
2023-12-31 | -1.06 | |
2023-09-30 | -0.91 | -0.91 |
2023-06-30 | -0.97 | -0.97 |
2023-03-31 | -2.87 | -2.87 |
2022-12-31 | -2.60 | |
2022-09-30 | -2.46 | -2.46 |
2022-06-30 | -2.32 | -2.32 |
2022-03-31 | -2.34 | -2.34 |
2021-12-31 | -2.39 | |
2021-09-30 | 0.24 | 0.24 |
2021-06-30 | 0.48 | 0.46 |
2021-03-31 | 0.51 | 0.49 |
2020-12-31 | 0.65 | 0.63 |
2020-09-30 | -2.21 | -2.22 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Denali Therapeutics Inc. per 2025 Jun 30 adalah -349.62 MM.
- Nilai cash from investing activities untuk Denali Therapeutics Inc. per 2025 Jun 30 adalah 442.55 MM.
- Nilai kas dari aktivitas pendanaan untuk Denali Therapeutics Inc. per 2025 Jun 30 adalah -24.87 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -349.62 | 442.55 | -24.87 |
2025-03-31 | -365.54 | 383.18 | -19.73 |
2024-12-31 | -347.69 | -88.76 | 484.30 |
2024-09-30 | -362.64 | -187.92 | 493.18 |
2024-06-30 | -390.86 | -180.66 | 514.23 |
2024-03-31 | -412.81 | -111.16 | 516.49 |
2023-12-31 | -357.99 | 249.31 | 17.82 |
2023-09-30 | -332.00 | 48.70 | 312.77 |
2023-06-30 | -301.68 | -36.79 | 315.43 |
2023-03-31 | -231.41 | -116.22 | 310.81 |
2022-12-31 | -244.72 | -141.39 | 310.67 |
2022-09-30 | -237.55 | -54.58 | 16.19 |
2022-06-30 | -221.94 | -123.00 | 14.35 |
2022-03-31 | -233.26 | -114.10 | 16.99 |
2021-12-31 | -211.39 | -21.63 | 19.35 |
2021-09-30 | 368.02 | -348.22 | 23.70 |
2021-06-30 | 409.54 | -507.33 | 446.29 |
2021-03-31 | 420.40 | -635.28 | 442.66 |
2020-12-31 | 416.15 | -623.21 | 634.75 |
2020-09-30 | -145.41 | -213.48 | 627.26 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/libro untuk Denali Therapeutics Inc. pada 2025 Jun 30 adalah 1.81.
- p/tbv untuk Denali Therapeutics Inc. pada 2025 Jun 30 adalah 1.81.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | 1.81 | 1.81 | |
2025-03-31 | 1.75 | 1.75 | |
2024-12-31 | 2.21 | 2.21 | |
2024-09-30 | -10.04 | 3.04 | 3.04 |
2024-06-30 | -24.13 | 2.28 | 2.28 |
2024-03-31 | -20.13 | 2.84 | 2.84 |
2023-12-31 | -23.81 | 2.65 | 2.65 |
2023-09-30 | -22.44 | 2.43 | 2.43 |
2023-06-30 | -10.85 | 4.16 | 4.16 |
2023-03-31 | -9.67 | 3.02 | |
2022-12-31 | 4.65 | 4.65 | |
2022-09-30 | 4.28 | 4.28 | |
2022-06-30 | -12.67 | 3.94 | 3.94 |
2022-03-31 | -13.59 | 4.10 | 4.10 |
2021-12-31 | 184.07 | 5.38 | 5.38 |
2021-09-30 | 109.73 | 5.72 | 5.72 |
2021-06-30 | |||
2021-03-31 | 52.54 | 2.75 | 2.75 |
2020-12-31 | 42.51 | 2.63 | 2.63 |
2020-09-30 | -13.20 | 3.41 | 3.41 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Denali Therapeutics Inc. pada 2025 Jun 30 adalah -0.23.
- EBIT (3 tahun) / EV untuk Denali Therapeutics Inc. pada 2025 Jun 30 adalah -0.17.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.23 | -0.17 |
2025-03-31 | -0.21 | -0.16 |
2024-12-31 | -0.15 | -0.11 |
2024-09-30 | -0.10 | -0.07 |
2024-06-30 | -0.04 | -0.08 |
2024-03-31 | -0.05 | -0.09 |
2023-12-31 | -0.04 | -0.05 |
2023-09-30 | -0.05 | -0.04 |
2023-06-30 | -0.09 | -0.05 |
2023-03-31 | -0.11 | -0.06 |
2022-12-31 | -0.08 | -0.05 |
2022-09-30 | -0.08 | -0.04 |
2022-06-30 | -0.08 | -0.04 |
2022-03-31 | -0.08 | -0.04 |
2021-12-31 | 0.01 | -0.01 |
2021-09-30 | 0.01 | -0.01 |
2021-06-30 | ||
2021-03-31 | 0.02 | -0.03 |
2020-12-31 | 0.03 | -0.02 |
2020-09-30 | -0.09 | -0.05 |
Efektivitas Manajemen
- roa untuk Denali Therapeutics Inc. pada 2025 Jun 30 adalah -0.30.
- roe untuk Denali Therapeutics Inc. pada 2025 Jun 30 adalah -0.33.
- roic untuk Denali Therapeutics Inc. pada 2025 Jun 30 adalah -0.39.
- croic untuk Denali Therapeutics Inc. pada 2025 Jun 30 adalah -0.00.
- ocroic untuk Denali Therapeutics Inc. pada 2025 Jun 30 adalah -0.31.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.30 | -0.33 | -0.39 | -0.00 | -0.31 |
2025-03-31 | -0.27 | -0.29 | -0.33 | 0.04 | -0.27 |
2024-12-31 | -0.37 | -0.41 | -0.31 | -0.04 | -0.26 |
2024-09-30 | -0.34 | -0.38 | -0.29 | -0.04 | -0.27 |
2024-06-30 | -0.10 | -0.14 | -0.09 | -0.00 | -0.27 |
2024-03-31 | -0.10 | -0.14 | -0.13 | -0.08 | -0.33 |
2023-12-31 | -0.10 | -0.15 | -0.11 | 0.03 | -0.28 |
2023-09-30 | -0.10 | -0.15 | -0.10 | -0.02 | -0.24 |
2023-06-30 | -0.29 | -0.42 | -0.10 | -0.02 | -0.24 |
2023-03-31 | -0.25 | -0.36 | -0.36 | -0.04 | -0.23 |
2022-12-31 | -0.21 | -0.30 | -0.35 | -0.32 | -0.27 |
2022-09-30 | -0.20 | -0.28 | -0.35 | -0.32 | -0.27 |
2022-06-30 | -0.19 | -0.27 | -0.30 | -0.35 | -0.23 |
2022-03-31 | -0.19 | -0.26 | -0.29 | -0.34 | -0.24 |
2021-12-31 | 0.02 | 0.03 | -0.28 | -0.21 | 0.34 |
2021-09-30 | 0.05 | 0.06 | 0.03 | 0.04 | 0.36 |
2021-06-30 | 0.09 | 0.11 | 0.05 | 0.31 | 0.36 |
2021-03-31 | 0.08 | 0.11 | 0.05 | 0.19 | 0.36 |
2020-12-31 | 0.13 | 0.18 | 0.06 | 0.35 | 0.34 |
2020-09-30 | -0.38 | -0.52 | -0.24 | 0.28 | -0.15 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | -332.55 | -331.22 | -390.85 |
2024-06-30 | -0.36 | -0.46 | -0.70 |
2024-03-31 | -0.28 | -0.44 | -0.60 |
2023-12-31 | -0.20 | -0.37 | -0.50 |
2023-09-30 | -0.18 | -0.37 | -0.48 |
2023-06-30 | -2.96 | -0.37 | -0.48 |
2023-03-31 | -2.31 | -3.65 | -3.89 |
2022-12-31 | -2.02 | -2.73 | -2.82 |
2022-09-30 | -1.83 | -2.73 | -2.82 |
2022-06-30 | -2.51 | -2.53 | -2.59 |
2022-03-31 | -4.45 | -3.45 | -3.51 |
2021-12-31 | 0.29 | -5.97 | -6.08 |
2021-09-30 | 0.34 | 0.08 | 0.07 |
2021-06-30 | 0.34 | 0.16 | 0.14 |
2021-03-31 | 0.35 | 0.17 | 0.15 |
2020-12-31 | 0.21 | 0.19 | |
2020-09-30 | -7.91 | -9.69 | -10.17 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1714899 |
Grupong Pang-industriya
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech) |